Correction: Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study (The Lancet Oncology (2017) 18(10) (1338–1347) (S1470204517306150) (10.1016/S1470-2045(17)30615-0));Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

The Lancet Oncology

Volumn 18, Issue 10, 2017, Pages 1338-1347

  Platzbecker, Uwe ^a   Germing, Ulrich ^b   Götze, Katharina S ^c   Kiewe, Philipp ^d   Mayer, Karin ^e   Chromik, Jörg ^f   Radsak, Markus ^g   Wolff, Thomas ^h   Zhang, Xiaosha ⁱ   Laadem, Abderrahmane ^j   Sherman, Matthew L ⁱ   Attie, Kenneth M ⁱ   Giagounidis, Aristoteles ^k  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d Onkologischer Schwerpunktam Oskar Helene Heim   (Germany)

^e UNIVERSITY HOSPITAL BONN   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g JOHANNES GUTENBERG UNIVERSITY   (Germany)

^h OncoResearch Lerchenfeld UG   (Germany)

ⁱ Acceleron Pharma   (United States)

^j CELGENE CORPORATION   (United States)

^k MARIEN HOSPITAL DÜSSELDORF   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; LUSPATERCEPT; ACTIVIN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BLAST CELL; BONE PAIN; CELL COUNT; CHRONIC MYELOMONOCYTIC LEUKEMIA; COHORT ANALYSIS; DECREASED APPETITE; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; FLATULENCE; GENE; GENE MUTATION; GENERAL CONDITION DETERIORATION; GERMANY; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERKALEMIA; HYPERTENSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE REACTION; INJECTION SITE SWELLING; INTENTION TO TREAT ANALYSIS; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LEUKOCYTE COUNT; LIMB PAIN; LONG TERM CARE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE HYPOTONIA; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLATELET COUNT; PRIORITY JOURNAL; PRURITUS; RASH; SF3B1 GENE; SIDE EFFECT; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; VOMITING; CLINICAL TRIAL; COMPLICATION; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTOR; TREATMENT OUTCOME;

ACTIVINS; ADULT; AGED; ANEMIA; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GERMANY; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85028655576     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30723-4     Document Type: Erratum

References (22)

1. Adès, L, Itzykson, R, Fenaux, P, Myelodysplastic syndromes. Lancet 383 (2014), 2239–2252.
2. Malcovati, L, Hellström-Lindberg, E, Bowen, D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122 (2013), 2943–2964.
3. Greenberg, P, Cox, C, LeBeau, MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997), 2079–2088.
4. Platzbecker, U, Hofbauer, LC, Ehninger, G, Hölig, K, The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk Res 36 (2012), 525–536.
5. Fenaux, P, Adès, L, How we treat lower-risk myelodysplastic syndromes. Blood 121 (2013), 4280–4286.
6. Sekeres, MA, Zell, K, Barnard, J, et al. Long-term outcome of myelodysplastic syndromes (MDS) patients treated with erythropoiesis stimulating agents (ESAs). Blood, 126, 2015 Abstr 1696.
7. Zhou, L, Nguyen, AN, Sohal, D, et al. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood 112 (2008), 3434–3443.
8. Zhou, L, McMahon, C, Bhagat, T, et al. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res 71 (2011), 955–963.
9. Bruns, I, Cadeddu, RP, Brueckmann, I, et al. Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. Blood 120 (2012), 2620–2630.
10. Bulycheva, E, Rauner, M, Medyouf, H, et al. Myelodysplasia is in the niche: novel concepts and emerging therapies. Leukemia 29 (2015), 259–268.
11. Suragani, RN, Cadena, SM, Cawley, SM, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med 20 (2014), 408–414.
12. Attie, KM, Allison, MJ, McClure, T, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol 89 (2014), 766–770.
13. Cheson, BD, Greenberg, PL, Bennett, JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108 (2006), 419–425.
14. Vardiman, JW, Thiele, J, Arber, DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114 (2009), 937–951.
15. Haferlach, T, Nagata, Y, Grossmann, V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28 (2014), 241–247.
16. Greenberg, PL, Tuechler, H, Schanz, J, et al. Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood 120 (2012), 2454–2465.
17. Santini, V, Almeida, A, Giagounidis, A, et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol 34 (2016), 2988–2996.
18. Visconte, V, Rogers, HJ, Singh, J, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood 120 (2012), 3173–3186.
19. Malcovati, L, Karimi, M, Papaemmanuil, E, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood 126 (2015), 233–241.
20. Papaemmanuil, E, Cazzola, M, Boultwood, J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 365 (2011), 1384–1395.
21. Chen, N, Laadem, A, Wilson, DM, et al. Pharmacokinetics and exposure–response of luspatercept in patients with anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS): preliminary results from phase 2 studies. Blood, 128, 2016 Abstr 1990.
22. Arber, DA, Orazi, A, Hasserjian, R, et al. World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127 (2016), 2391–2405.